Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
127.5 USD | -0.60% | -3.69% | +32.57% |
Financials (USD)
Sales 2024 * | 1.93B | Sales 2025 * | 2.79B | Capitalization | 12.13B |
---|---|---|---|---|---|
Net income 2024 * | 313M | Net income 2025 * | 955M | EV / Sales 2024 * | 5.75 x |
Net cash position 2024 * | 1.03B | Net cash position 2025 * | 2.54B | EV / Sales 2025 * | 3.43 x |
P/E ratio 2024 * |
39.7
x | P/E ratio 2025 * |
12.4
x | Employees | 1,314 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.03% |
Latest transcript on Sarepta Therapeutics, Inc.
1 day | -0.65% | ||
1 week | -3.69% | ||
Current month | +0.93% | ||
1 month | +9.15% | ||
3 months | -6.36% | ||
6 months | +54.27% | ||
Current year | +32.57% |
Managers | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
Ian Estepan
DFI | Director of Finance/CFO | 48 | 14-12-31 |
Bilal Arif
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Douglas Ingram
CEO | Chief Executive Officer | 61 | 17-06-25 |
M. Wilsey
CHM | Chairman | 71 | 09-03-30 |
Richard Barry
BRD | Director/Board Member | 65 | 15-06-01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.63% | 1 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-23 | 127.8 | -0.36% | 147 017 |
24-05-22 | 128.3 | -0.64% | 723,257 |
24-05-21 | 129.1 | -1.31% | 748,484 |
24-05-20 | 130.8 | -0.42% | 779,919 |
24-05-17 | 131.4 | -1.02% | 849,008 |
Delayed Quote Nasdaq, May 23, 2024 at 10:52 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.57% | 12.13B | |
+10.29% | 115B | |
+12.70% | 106B | |
-4.37% | 24.69B | |
-2.01% | 21.97B | |
-5.57% | 19.27B | |
-11.69% | 17.56B | |
-39.36% | 17.32B | |
+6.02% | 14.03B | |
-31.76% | 7.77B |
- Stock Market
- Equities
- SRPT Stock